Abciximab or eptifibatide in percutaneous coronary intervention: In-hospital outcomes and costs and six-month results

International Journal of Angiology

Volumn 11, Issue 4, 2002, Pages 221-224

  Burgess, Brett C ^a   Hanna Moussa, Shafik ^a   Ramasamy, Kala ^a   Sigler, Diana ^a   David, Shukri ^a,b  

^a Providence Medical Center   (United States)

^b PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG INDICATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMATOMA; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0036768367     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-002-0927-5     Document Type: Article

References (16)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242-250;310-318.
2. Erbel R, Heusch G (1999) Coronary microembolization - its role in acute coronary syndromes and interventions. Herz 24:558-575.
3. Lefkovits J, Plow EF, Topol EJ (1995) Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332:1553-1559
4. The EP1C Investigators (1994) Use of a monoclonal antibody directed against platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961.
5. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-close heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696.
6. The EPISTENT Investigators (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87-92.
7. The ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356:2037-2044.
8. The IMPACT-II Investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349:1422-1428.
9. Talley JD (2002) Pharmacology of GP IIb-IIIa platelet inhibitors. J Intervent Cardiol 13:243-254.
10. Changezi M, Schweiger MJ, Prescod D, Cook JR (1999) Comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention [abstract]. Circulation 100(suppl):1-187.
11. The PRICE Investigators (2001) Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie Reo-Pro versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J 141:402-409.
12. Laskey WK, Williams DO, Vlachos HA, Cohen H, Holmes DR, King SB, Kelsey SF, Slater J, Faxon D, Al-Bassam M, Block E, Detre KM (2001) Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the national heart, lung, and blood institute (NHLBI) dynamic registry. An J Cardiol 87:964-969.
13. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE, for the ESPRIT Investigators (2001) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial. JAMA 285:2468-2473.
14. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann F-J, Stone GW, DiBattiste PM, Yakubov SJ, DeLucca PT, Demopoulos LA, for the TARGET Investigators (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 244:1888-1894.
15. The RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453.
16. Simon DI, Liu CB, Ganz P, Kirshenbaum JM, Piana RN, Rogers C, Selwyn AP, Popma JJ (2001) A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Cathet Cardiovasc Intervent 52:425-432.